Incidence, clinical features and risk factors of interstitial pneumonia in children with acute lymphoblastic leukemia. [PDF]
Li Y +12 more
europepmc +1 more source
A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias [PDF]
Benoit, Yves +20 more
core
NOTCH signalling is indispensable for tissue homeostasis and, consequently, corruption of its normal function promotes numerous diseases, including cancer. However, the development of targeted therapies has been hampered by inefficacy and overt toxicity. Here, we show that NOTCH receptor dimerization is necessary for receptor transactivation, which has
Xinxin Liu +9 more
wiley +1 more source
Multi-Omics Applications in Adult Acute Lymphoblastic Leukemia: From Biological Mechanisms to Precision Therapies. [PDF]
Simio C, Molica M, De Fazio L, Rossi M.
europepmc +1 more source
Bringing Gene Therapy Into Real World Clinical Practice
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach +2 more
wiley +1 more source
Identification of the Philadelphia-like subgroup in Turkish pediatric patients with acute lymphoblastic leukemia. [PDF]
Efendi Erdem E +9 more
europepmc +1 more source
Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
ABSTRACT Introduction Valoctocogene roxaparvovec is an adeno‐associated virus vector serotype 5 (AAV5)‐mediated gene therapy for severe haemophilia A (HA). Aim Report the final safety and efficacy results of the phase 1/2 trial of valoctocogene roxaparvovec. Methods An open‐label phase 1/2 trial (NCT02576795) enrolled adult males with severe HA (factor
Priyanka Raheja +9 more
wiley +1 more source
SETD4 as a marker of disease burden and treatment response in childhood acute lymphoblastic leukemia<i>SETD4</i> as a marker of disease burden and treatment response in childhood acute lymphoblastic leukemia. [PDF]
Telles LAM +5 more
europepmc +1 more source
ABSTRACT Background Inherited platelet disorders (IPDs) are rare hematologic conditions encompassing a heterogeneous spectrum of quantitative and qualitative platelet defects, frequently associated with variable clinical phenotypes and comorbidities. Accurate diagnosis necessitates comprehensive genetic characterization, detailed clinical and bleeding ...
Silvia Ferrari +6 more
wiley +1 more source

